Video summary

The Most Underrated Metabolic Compound of All Time Has Been Discovered (better than NAD+)

Main summary

Key takeaways

Science and Nature

Scientific Concepts, Discoveries, and Nature/Biological Phenomena

Niacin (Vitamin B3) and Cellular Signaling

  • Niacin is an essential vitamin required for survival.
  • Main known biochemical roles discussed:
    • NAD (nicotinamide adenine dinucleotide) synthesis
    • Recycling of NAD
  • Niacin as a receptor agonist:
    • Niacin acts as an agonist for the GPR109A receptor (a GPCR; “GPR” = G protein-coupled receptor).
    • Mentioned condition effect: niacin can cause flushing (vasodilatory effect).

Beta-Hydroxybutyrate (BHB) / Ketones and GPR109A

  • BHB is produced during ketosis (e.g., ketogenic diet, fasting).
  • Alternative function of BHB (beyond energy): it is also described as an agonist for GPR109A.
  • Role of GPR109A in metabolism:
    • GPR109A signaling is described as inhibiting cyclic AMP (cAMP).
    • cAMP is described as promoting fat mobilization in adipocytes (high cAMP → fat mobilization; inhibiting cAMP → reduces it).
    • Analogy: caffeine increases cAMP (non-specific secondary messenger comparison).

Implications for Fat Mobilization and Exercise/Energy Perception

  • If GPR109A activation lowers cAMP, the talk suggests it could reduce fat mobilization, potentially:
    • in theory, blunting fat loss if niacin/BHB signaling is strong enough.
    • practically, any effect may be small and/or visible over long time horizons, not immediately pre-exercise.
  • Reported real-world note (non-mechanistic): some people feel “activated” from niacin flushing/energy effects; the speaker suggests this may be largely perception-driven.

Kidney Disease and cAMP as a Driver (PKD and CFTR)

PKD (Polycystic Kidney Disease) Pathogenesis via cAMP

  • Central disease mechanism described:
    • Overactive cAMP signaling drives cyst formation and growth in kidney tubules.
  • Therapeutic parallel: tolvaptan
    • Mentioned drug: tolvaptan, described as acting through vasopressin V2 receptor pathways to reduce the cAMP increase.
    • The speaker frames GPR109A activation (via BHB/niacin) as a different way to lower cAMP, potentially affecting cyst growth.

CFTR Channel Involvement

  • CFTR (cystic fibrosis transmembrane conductance regulator) is described as:
    • activated by cAMP
    • a chloride channel whose activation contributes to cyst enlargement (chloride pumping into the cyst lumen → cyst growth).
  • Therefore, lowering cAMP could reduce:
    • cyst signaling drivers
    • CFTR activity

“Kidneys Are Ketogenic”: BHB Production/Handling Inside the Nephron

The speaker claims:

  • Kidneys both produce and consume BHB.
  • Within the nephron/tubule, BHB can be produced near mitochondria-rich cells and then:
    • traverse tubule lumen, or
    • be recycled back along nephron segments (“conjunction”/loop described)
  • Proposed functional outcome:
    • BHB recycling may increase filtration/solute flow, acting as a boost for nephron function.
  • For healthy kidneys, the talk suggests that improved filtration could yield downstream benefits, including systemic effects (electrolyte balance mentioned).

Gut–Kidney Axis and Uremic Toxins

  • If kidneys can’t clear uremic waste:
    • toxins are redirected into the gut
    • gut environment and microbiome may shift
    • bacterial consumption and barrier (cell/mucosal) alterations can occur
  • Soluble fiber:
    • suggested as a potentially “clever” way to help bind/remove toxins in this context.
  • CKD link to gut pathology:
    • CKD is described as associated with gut dysbiosis and intestinal permeability.
    • The speaker suggests a feed-forward cycle:
      • gut injury → worsens kidney injury → further gut effects.

Ketones in the Gut: Receptor-Mediated Anti-Inflammatory Changes

Butyrate and “Ketone-Like” Receptor Effects

  • The speaker studied butyrate delivery:
    • tributyrin (a triglyceride prodrug with three butyrate molecules) is metabolized in the gut into butyrate.
  • Claimed gut benefits with tributyrin:
    • improved barrier integrity
    • improved mucus production
    • better localization of barrier-related proteins
  • Both butyrate and BHB are said to bind/activate GPR109A (with the acknowledgment that multiple receptors may be involved).

Why BHB Is Hard to Replace with “Normal Gut Physiology”

  • Speaker emphasis:
    • Under normal conditions, gut bacteria primarily produce butyrate, not BHB.
    • BHB in the gut becomes prominent under ketosis due to described leakiness/transport from blood/luminal side into the gut environment.
  • Proposed gut mechanism (anti-inflammatory):
    • Enterocytes have GPR109A
    • BHB likely modulates inflammatory state through this receptor
    • Deleting/removing the receptor is described as changing the microbiome composition significantly
    • Result: an anti-inflammatory microbiome may emerge.

Microbiome–Immune Signaling Concept

The talk describes a chain:

  • BHB/ketones change the gut environment → change microbiome species → immune cells and nearby cellular layers “sample” luminal conditions → immune activation patterns change → inflammation level and barrier state shift

Evidence Timeline in Animals

  • Rodent studies described:
    • rapid gut changes after feeding ketones (as early as 4–5 days)
    • longer studies also show changes (up to ~3 months)
  • Rodent-to-human limitation:
    • differences in gut fermentation capacity and gut length/digestion timing affect translation.

BHB “Elation” (A Post-Translational Modification Concept)

  • BHB elation is described as:
    • a modification akin to acetylation, but using BHB (added to proteins)
    • changes protein function and potentially affects gene/protein regulation
  • Conceptual purpose:
    • metabolites act as state signals to coordinate metabolism with cellular systems.
  • Speaker implication:
    • this may be a driver behind disease-modifying effects seen with ketosis/ketones.

D-BHB vs L-BHB (Energetic vs Signaling Roles)

  • Mention of research comparing D-BHB and L-BHB:
    • D-BHB is rapidly metabolized (converted toward normal ketone metabolism).
    • L-BHB is described as not readily metabolizable via Krebs, but may still exert signaling effects.
  • Contextual note:
    • L-BHB elevations are mentioned in heart injury, interpreted as potentially signaling-linked.

Exogenous Ketones: Dosing and Measurement Caveats

Blood Levels vs Tissue Effects

  • Key claims/points:
    • Blood BHB levels may not reflect tissue-level effects.
    • Ketone effects can be detected through pathway changes even when blood meters show little difference.
    • Ketone levels fluctuate quickly; blood snapshots may miss dynamic signaling.

Keeping Ketones “Not Too High”

  • Anecdotal protocol logic:
    • some practitioners keep ketones below very high levels and adjust intake (example given: adding carbs like mango if ketones rise too much), implying:
      • tissue signaling may not require maximal circulating ketone levels.

Why Esters vs Salts vs Butanediol

  • Discussed as different ways to raise ketones:
    • Ketone salts:
      • described as beneficial and comparatively effective/safer (in the speaker’s kidney disease model)
    • Butanediol:
      • argued to be worse for kidney outcomes; proposed reason:
        • it consumes NAD to convert into BHB (potential liver cost; maybe kidney cost too)
    • Monoesters:
      • described as interesting but can involve:
        • insulin spikes
        • “cost prohibitive” for long-term general use
  • Use-case framing:
    • esters may make sense in performance settings—especially when co-ingested carbs create high insulin + ketones.
  • General recommendation:
    • ketone salts may be an inexpensive way to get benefits without strict ketogenic diets.

Takeaway Application for Aging and Kidney Risk (Protocol Direction, Not Formal Dosing)

For kidney disease risk (family history/CKD context), the speaker’s view:

  • Exogenous ketones likely help kidney function (based on research experience).
  • Ketogenic diet / intermittent ketosis also has a place.
  • A specific product/company mentioned as designed for kidney-focused ketone delivery:
    • Keto Citra (citrate + D/L BHB), framed for kidney function and potentially PKD/CKD general health.

Methods / Approach Outlined (Implied; Not a Lab Protocol)

Disease Mechanism Targeting

Lower cAMP signaling in kidney cystic disease using different upstream routes:

  • known approach:
    • tolvaptan (vasopressin V2 pathway → reduces cAMP rise)
  • hypothesized alternative:
    • activate GPR109A with BHB or niacin → inhibit cAMP → potentially reduce cyst growth and CFTR activity

Gut-Barrier Improvement Strategy

  • Use receptor-relevant metabolites or prodrugs:
    • tributyrin → butyrate in gut → improves barrier/mucus
    • ketones during ketosis → promote anti-inflammatory microbiome and barrier effects via GPR109A

Research Framing and Limitations

  • Compare ketogenic-related metabolites at:
    • tissue-level pathways
    • receptor-level mechanisms (GPR109A)
  • Note limitations:
    • blood BHB ≠ tissue effects
    • rodent gut differences vs humans

Researchers / Sources Featured (Named or Explicitly Cited)

  • Dr. Jacob Torres (speaker)
  • Dom D’Agostino (mentioned discussing ketone management in practice)
  • Chris Masterjohn (mentioned in relation to exogenous ketones signaling/feedback loop)

Original video